By Stephen Nakrosis

Biopharmaceutical company Bionomics Ltd. filed for an initial public offering with the U.S. Securities and Exchange Commission on Monday.

The company's shares currently trade on the Australian Securities Exchange under the symbol BNO. The company said it planned to offer American depositary shares on the Nasdaq Global Market under the symbol BNOX.

Bionomics said its lead product candidate, BNC210, is for acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. "There remains a significant unmet medical need for the over 22 million patients in the United States alone suffering from SAD and PTSD," the company said.

BVF Partners L.P. and Apeiron Investment Group Ltd. are listed among the company's principal shareholders.

Bionomics didn't give an expected size for its offering, nor did it provide an expected price range.

Evercore ISI, William Blair, Cantor, Berenberg and H.C. Wainwright & Co. are listed as the offering's underwriters.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

November 22, 2021 18:19 ET (23:19 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Bionomics (ASX:BNO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Bionomics.
Bionomics (ASX:BNO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Bionomics.